Alerts will be sent to your verified email
Verify Email
BALAXI
|
Balaxi Pharma.
|
Krebs Biochem.&Inds
|
Coral Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
27.3 % | 37.05 % | 8.16 % |
|
5yr average Equity Multiplier
|
1.4 | -2.13 | 1.18 |
|
5yr Average Asset Turnover Ratio
|
1.43 | 0.3 | 0.47 |
|
5yr Avg Net Profit Margin
|
11.03 % | -55.19 % | 14.82 % |
|
Price to Book
|
0.66 | 0.0 | 0.74 |
|
P/E
|
10.77 | 0.0 | 9.09 |
|
5yr Avg Cash Conversion Cycle
|
154.28 Days | -1144.52 Days | 35.5 Days |
|
Inventory Days
|
87.41 Days | 102.59 Days | 69.25 Days |
|
Days Receivable
|
103.86 Days | 8.23 Days | 98.13 Days |
|
Days Payable
|
63.18 Days | 623.06 Days | 131.4 Days |
|
5yr Average Interest Coverage Ratio
|
57.05 | -4.97 | 171.88 |
|
5yr Avg ROCE
|
36.52 % | -23.43 % | 10.48 % |
|
5yr Avg Operating Profit Margin
|
16.64 % | -34.39 % | 14.88 % |
|
5 yr average Debt to Equity
|
0.09 | -1.88 | 0.02 |
|
5yr CAGR Net Profit
|
-5.76 % | -0.84 % | 12.26 % |
|
5yr Average Return on Assets
|
18.47 % | -16.47 % | 6.95 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
65.99 % | 72.74 % | 71.51 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.87 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Balaxi Pharma.
|
Krebs Biochem.&Inds
|
Coral Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|